Compare CAC & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAC | TBPH |
|---|---|---|
| Founded | 1875 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.2M | 824.9M |
| IPO Year | 1996 | 2013 |
| Metric | CAC | TBPH |
|---|---|---|
| Price | $50.57 | $16.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $45.50 | $18.40 |
| AVG Volume (30 Days) | 91.3K | ★ 464.0K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.28% | N/A |
| EPS Growth | 6.08 | ★ 279.13 |
| EPS | ★ 3.84 | 2.06 |
| Revenue | ★ $41,739,000.00 | $15,386,000.00 |
| Revenue This Year | $19.15 | $1.04 |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | $13.34 | ★ $8.36 |
| Revenue Growth | ★ 16.96 | N/A |
| 52 Week Low | $35.00 | $8.33 |
| 52 Week High | $52.17 | $21.03 |
| Indicator | CAC | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 59.66 | 57.37 |
| Support Level | $41.94 | $13.41 |
| Resistance Level | $51.37 | $19.04 |
| Average True Range (ATR) | 1.09 | 0.48 |
| MACD | 0.14 | 0.17 |
| Stochastic Oscillator | 67.72 | 72.58 |
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.